Cargando…
Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease
ABSTRACT: The current outbreak of the highly transmittable and life-threatening severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved rapidly and posed a global health emergency. Many clinical trials are now being conducted to test possible therapies. To assist this, virtual scree...
Autores principales: | Hussien, Mostafa A., Abdelaziz, Ahmed E. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413836/ https://www.ncbi.nlm.nih.gov/pubmed/32834922 http://dx.doi.org/10.1007/s13721-020-00263-6 |
Ejemplares similares
-
Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations
por: Omer, Samia E., et al.
Publicado: (2022) -
Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023) -
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021) -
A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme()
por: Ercan, Selami, et al.
Publicado: (2021) -
Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
por: Hakmi, Mohammed, et al.
Publicado: (2020)